Lucira Health, Inc. (LHDX): Price and Financial Metrics


Lucira Health, Inc. (LHDX): $5.30

-0.12 (-2.21%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

LHDX Stock Price Chart Interactive Chart >

Price chart for LHDX

LHDX Price/Volume Stats

Current price $5.30 52-week high $37.99
Prev. close $5.42 52-week low $4.23
Day low $5.25 Volume 289,504
Day high $5.86 Avg. volume 238,321
50-day MA $6.77 Dividend yield N/A
200-day MA $6.98 Market Cap 207.89M

Lucira Health, Inc. (LHDX) Company Bio


Lucira Health, Inc. produces and distributes medical equipment. The Company offers disposable test kits to detect DNA and RNA of infectious diseases. Lucira Health markets its products in the United States.


LHDX Latest News Stream


Event/Time News Detail
Loading, please wait...

LHDX Latest Social Stream


Loading social stream, please wait...

View Full LHDX Social Stream

Latest LHDX News From Around the Web

Below are the latest news stories about Lucira Health Inc that investors may wish to consider to help them evaluate LHDX as an investment opportunity.

Roche to offer 'tens of millions' of at-home Covid tests by end of month

The rollout comes amid long lines at testing sites and President Joe Biden's promise to increase the number of tests available.

Yahoo | January 11, 2022

Lucira™ Check-It PCR-Quality, At-Home Molecular COVID-19 Test Now Available in the Optum Store

Lucira's COVID-19 test is the only EUA authorized rapid at-home self-test that delivers PCR accuracy and early detectability in a single-use test kit with results in 30 minutes Availability in the Optum Store expands access to this unique testing option amidst a surge of US COVID-19 cases caused by the Omicron variant Lucira's test uniquely offers PCR accuracy and early detection without the 24 hour+ wait for results EMERYVILLE, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Luc

Yahoo | January 11, 2022

Lucira Health Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2021 and Provides Business Update

EMERYVILLE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced preliminary revenue results for the fourth quarter and full year 2021. Preliminary, unaudited revenue for the fourth quarter 2021 is expected to be between $58 million and $60 million, reflecting growth of approximately 300% over the unaudite

Yahoo | January 10, 2022

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Lucira Health, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 31, 2021 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lucira Health, Inc. ("Lucira" or "the Company") (NASDAQ:LHDX) for violations of the securities laws.

Yahoo | January 1, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lucira Health, Inc. - LHDX

Pomerantz LLP is investigating claims on behalf of investors of Lucira Health, Inc. ("Lucira" or the "Company") (NASDAQ: LHDX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Yahoo | December 30, 2021

Read More 'LHDX' Stories Here

LHDX Price Returns

1-mo -23.08%
3-mo -10.02%
6-mo -33.58%
1-year N/A
3-year N/A
5-year N/A
YTD -38.44%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.765 seconds.